Key result
Oral MK-996 inhibits angiotensin II pressor responses and reduces blood pressure in preclinical models.
Why the study?
A potent, orally active, highly selective nonpeptide angiotensin II receptor antagonist with consistent pharmacologic profile across species and antihypertensive activity was needed.
Does MK-996 inhibit the pressor response to angiotensin II and reduce blood pressure in animal models?
Population
Conscious rat, dog, rhesus monkey, anesthetized chimpanzee, and aortic coarcted rats
Comparison
MK-996 vs losartan and enalapril in aortic coarcted rats
Design
Preclinical pharmacology study
Follow-up
Up to 24 hours
Authors
Loading...
May warrant first-in-human trials; leaves open translation of antihypertensive effects to patients.
Does MK-996 inhibit the pressor response to angiotensin II and reduce blood pressure in animal models?
MK-996 is a potent, orally active, nonpeptide angiotensin II receptor antagonist with antihypertensive activity and minimal species variability in preclinical models.
Kivlighn et al. (1995) studied Hypertension (animal models). MK-996 vs. Losartan and enalapril was evaluated on Inhibition of angiotensin II pressor response and blood pressure reduction. MK-996 is a potent, orally active angiotensin II receptor antagonist that inhibits the AII pressor response across multiple species and reduces blood pressure in high-renin rats.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: